ClinTec International Expands Further in MENA Region with Proposed Opening of Istanbul Office
ClinTec International, a global CRO with a presence in over 40 countries worldwide, announced its intention to formally open an office in Istanbul, Turkey. The office will not only provide ClinTec’s global team with access to a new patient population, but will also further consolidate the British CRO’s presence in the Middle East and North Africa (MENA) region. The office adds to the company’s current MENA region offices based in Cairo, Egypt, Dubai Health Care City, UAE, and Beirut, Lebanon.
Speaking at the announcement of ClinTec’s new office, the company’s founder and CEO, Dr Rabinder Buttar commented; “The launch of this new office in Turkey confirms ClinTec International’s reputation as a truly global provider of quality assured clinical research services. It also reflects the growing significance of Turkey- and the wider MENA region- to the global clinical research market. We are delighted to be at the forefront of developing expertise in Turkey and the MENA region as a whole.”
If you would like further information on ClinTec International, our new offices, or details of our training schemes, including the new MSc International Clinical Research and Technology please contact:
Bobby Bal, Senior Director, Corporate Development,
Glasgow, Scotland, UK.
Phone: +44 (0)141 226 1120
Fax: +44 (0)141 248 8993
Email : [email protected]www.clintec.com
Moderna’s mRNA-1010 Flu Vaccine Meets Efficacy Goals in Phase III Trial of Adults 50+
July 10th 2025In the P304 Phase III study, Moderna’s mRNA-1010 demonstrated a 26.6% relative efficacy over a standard-dose flu vaccine in adults aged 50+, showing consistent protection across strains and age groups.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.
